(Total Views: 633)
Posted On: 04/27/2021 7:20:16 PM
Post# of 148899
Re: Evil Rabbit #88123
“If you disagree and think the FDA has done no wrong, as you've posted everywhere, then you must believe Nader is telling the truth about the FDA.”
NP consistently misleads investors so it’s impossible to know when he’s telling the truth or lying. Perfect example: the last Proactive when he told us a leading Wallstreet Investor, with top analysts, did their DD and invested $50 million. That was a lie because we knows the $50 million came from Fife, who’s under investigation by the SEC, and who is not a top Wall Street investor. He’s a loan shark for OTC companies who pay in shares and who can’t get money anywhere else.
The FDA played a role in the delay of trials, but to blame them completely would require ignoring the lack of expertise of the CYDY team, including NP, who is more worried about lining his pockets with money (reference two lawsuits they’ve had to settle) then paying for a good CRO and CSO.
Here’s an example of why CYDY is also to blame for trial issues. According to PRs and CCs, NP and CYDY submitted the 1st version of the CD16 protocol with only 2 doses to the FDA. This is the protocol that was mentioned in the March 6th PR. How do we know that it was submitted with only 2 doses? Well, 24 days later CYDY released the 14 day mortality data with a statement at the bottom from NP saying that the 14 day data suggests 3-4 doses. The modified protocol with 4 doses was submitted a few days later. So, if CYDY fought so hard for 4 doses in April of 2020 (they didn’t), then why did they submit the initial CD16 with only 2 doses? The answer is that the company is inept due to lack of leadership and a good CSO/CMO. This investor board knew last summer that more than 2 doses were needed, but that didn’t stop NP from submitting a protocol to the FDA with 2 doses. Yes, CYDY is part of the problem.
NP consistently misleads investors so it’s impossible to know when he’s telling the truth or lying. Perfect example: the last Proactive when he told us a leading Wallstreet Investor, with top analysts, did their DD and invested $50 million. That was a lie because we knows the $50 million came from Fife, who’s under investigation by the SEC, and who is not a top Wall Street investor. He’s a loan shark for OTC companies who pay in shares and who can’t get money anywhere else.
The FDA played a role in the delay of trials, but to blame them completely would require ignoring the lack of expertise of the CYDY team, including NP, who is more worried about lining his pockets with money (reference two lawsuits they’ve had to settle) then paying for a good CRO and CSO.
Here’s an example of why CYDY is also to blame for trial issues. According to PRs and CCs, NP and CYDY submitted the 1st version of the CD16 protocol with only 2 doses to the FDA. This is the protocol that was mentioned in the March 6th PR. How do we know that it was submitted with only 2 doses? Well, 24 days later CYDY released the 14 day mortality data with a statement at the bottom from NP saying that the 14 day data suggests 3-4 doses. The modified protocol with 4 doses was submitted a few days later. So, if CYDY fought so hard for 4 doses in April of 2020 (they didn’t), then why did they submit the initial CD16 with only 2 doses? The answer is that the company is inept due to lack of leadership and a good CSO/CMO. This investor board knew last summer that more than 2 doses were needed, but that didn’t stop NP from submitting a protocol to the FDA with 2 doses. Yes, CYDY is part of the problem.
(10)
(7)Scroll down for more posts ▼
